Literature DB >> 7773533

Mediation of noradrenaline-induced contractions of rat aorta by the alpha 1B-adrenoceptor subtype.

R Testa1, L Guarneri, E Poggesi, I Simonazzi, C Taddei, A Leonardi.   

Abstract

1. The subtypes of alpha 1-adrenoceptor mediating contractions to exogenous noradrenaline (NA) in rat aorta have been examined in both biochemical and functional studies. 2. Incubation of rat aortic membranes with the irreversible alpha 1B-adrenoceptor antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). 3. Contractions of rat aortic strips to NA after CEC (50 microM for 30 min) incubation followed by repetitive washing, showed a marked shift in the potency of NA and a partial reduction in the maximum response. The residual contractions to NA after CEC incubation were not affected by prazosin (10 nM). 4. The competitive antagonists prazosin, terazosin, (R)-YM-12617, phentolamine, 5-methylurapidil and spiperone inhibited contractions to NA with estimated pA2 values of 9.85, 8.54, 9.34, 7.71, 7.64 and 8.41, respectively. 5. The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas spiperone was alpha 1B-selective. 6. A significant correlation was found between the pA2 values of the alpha 1-adrenoceptor antagonists tested and their affinity for the alpha 1B-adrenoceptor subtype, but not for the alpha 1A-subtype. 7. In conclusion, these findings indicate that in rat aorta most of the contraction is mediated by alpha 1B-adrenoceptors, and that the potency (pA2) of an antagonist in this tissue should be related to its antagonistic effect on this subtype of the alpha 1-adrenoceptor population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773533      PMCID: PMC1510206          DOI: 10.1111/j.1476-5381.1995.tb13267.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

Review 1.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+.

Authors:  K P Minneman
Journal:  Pharmacol Rev       Date:  1988-06       Impact factor: 25.468

2.  Subtypes of alpha 1-adrenoceptors involved in noradrenaline-induced contractions of rat thoracic aorta and dog carotid artery.

Authors:  I Muramatsu; S Kigoshi; T Ohmura
Journal:  Jpn J Pharmacol       Date:  1991-12

3.  Comparative study of postsynaptic alpha-adrenoceptors in aorta obtained from human and other mammalian species.

Authors:  E Martinotti; M C Breschi; C Omini; M Pani; M A Ciucci; P Nieri
Journal:  Pharmacol Res       Date:  1991-01       Impact factor: 7.658

4.  Receptor protection studies with phenoxybenzamine indicate that a single alpha 1-adrenoceptor may be coupled to two signal transduction processes in vascular smooth muscle.

Authors:  M A Oriowo; A J Nichols; R R Ruffolo
Journal:  Pharmacology       Date:  1992       Impact factor: 2.547

5.  Species heterogeneity of hepatic alpha 1-adrenoceptors: alpha 1A-, alpha 1B- and alpha 1C-subtypes.

Authors:  J A García-Sáinz; M T Romero-Avila; R Alcántara Hernández; M Macias-Silva; A Olivares-Reyes; C González-Espinosa
Journal:  Biochem Biophys Res Commun       Date:  1992-07-31       Impact factor: 3.575

6.  Chloroethylclonidine unmasks a non-alpha-adrenoceptor noradrenaline binding site in the rat aorta.

Authors:  M A Oriowo; J A Bevan
Journal:  Eur J Pharmacol       Date:  1990-03-20       Impact factor: 4.432

7.  Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Mol Pharmacol       Date:  1987-10       Impact factor: 4.436

8.  Species differences in chlorethylclonidine antagonism at vascular alpha-1 adrenergic receptors.

Authors:  W N Tian; S Gupta; R C Deth
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

9.  Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle.

Authors:  I Muramatsu; T Ohmura; S Kigoshi; S Hashimoto; M Oshita
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

10.  Subtypes of alpha 1-adrenoceptors in rat blood vessels.

Authors:  C Han; J Li; K P Minneman
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

View more
  6 in total

1.  Functional evidence of inverse agonism in vascular smooth muscle.

Authors:  M A Noguera; M D Ivorra; P D'Ocon
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

2.  Insights into the functional roles of alpha(1)-adrenoceptor subtypes in mouse carotid arteries using knockout mice.

Authors:  Clare Deighan; Laura Methven; Mustafa M Naghadeh; Alexis Wokoma; Joyce Macmillan; Craig J Daly; Akito Tanoue; Gozoh Tsujimoto; John C McGrath
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

3.  Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes.

Authors:  T Kobayashi; K Kamata
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

4.  A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype.

Authors:  Y Madrero; M Elorriaga; S Martinez; M A Noguera; B K Cassels; P D'Ocon; M D Ivorra
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

5.  Characterization of alpha1-adrenoceptor subtypes mediating vasoconstriction in human umbilical vein.

Authors:  A E Errasti; M P Velo; R M Torres; S P Sardi; R P Rothlin
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Analysis of the activity of alpha 1-adrenoceptor antagonists in rat aorta.

Authors:  P H Van der Graaf; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.